Literature DB >> 9055784

Intranasal midazolam in patients with status epilepticus.

J L Kendall1, M Reynolds, R Goldberg.   

Abstract

The patient in status epilepticus presents many challenges to the emergency physician. IV access is frequently difficult to achieve, and prolonged attempts at access can jeopardize the patient and endanger the caregiver. We present two cases in which the administration of intranasal midazolam appeared to successfully terminate status epilepticus. No adverse effects were noted. Studies are needed to clarify the safety, optimal dosing, and clinical utility of this treatment modality.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055784     DOI: 10.1016/s0196-0644(97)70356-1

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  6 in total

1.  Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.

Authors:  P D Knoester; D M Jonker; R T M Van Der Hoeven; T A C Vermeij; P M Edelbroek; G J Brekelmans; G J de Haan
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

Review 2.  Treatment of status epilepticus in children.

Authors:  M De Negri; M G Baglietto
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Status epilepticus: an evidence based guide.

Authors:  Matthew Walker
Journal:  BMJ       Date:  2005-09-24

Review 4.  Status epilepticus. Current concepts and management.

Authors:  E Starreveld; A A Starreveld
Journal:  Can Fam Physician       Date:  2000-09       Impact factor: 3.275

5.  Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: a randomized clinical trial.

Authors:  Mohsen Javadzadeh; Kourosh Sheibani; Mozhgan Hashemieh; Hedyeh Saneifard
Journal:  Iran J Pediatr       Date:  2012-03       Impact factor: 0.364

6.  Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging.

Authors:  Nisha Singh; Mattia Veronese; Jim O'Doherty; Teresa Sementa; Salvatore Bongarzone; Diana Cash; Camilla Simmons; Marco Arcolin; Paul K Marsden; Antony Gee; Federico E Turkheimer
Journal:  Nucl Med Biol       Date:  2018-08-30       Impact factor: 2.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.